- About Terumo
- Business Overview
- May 17, 2022Corporate
- May 16, 2022Corporate
- Global Network
Blood and Cell Technologies Company
Terumo Blood and Cell Technologies
Unlocking the potential of blood and cells for patients and their quality of life
Blood and cells are indispensable in sustaining our lives, and at the same time, they hold the potential to treat cancer and other serious diseases. The Blood and Cell Technologies Company, which is headed by the subsidiary Terumo Blood and Cell Technologies, provides devices to safely and efficiently process donated blood into blood products and to collect blood components needed for transfusions and cell therapy. The company also offers automation and workflow efficiency solutions to support pharmaceutical company’s manufacturing process for cell therapies.
The company will continue to advance its unique technologies to provide patients with new treatment options.
Note: The regulatory approval status and availability of these products differ by country or region.
Blood Centers Solutions
Blood from donations is processed at blood centers into products including platelets, plasma, and red blood cells, then supplied to medical institutions. Terumo provides blood centers with blood collection instruments, disposable kits, whole blood bags, and devices used to process blood products.
Whole blood collection
Blood separation and component production
Pathogen reduction technology
Therapeutic Apheresis and Cell Collection
Terumo provides a centrifugal apheresis system that separates, collects, or removes blood components. Through a variety of blood component removal therapies or collection, we provide patients with new treatment options.
This technology efficiently processes the cells needed for use in therapy and research. It is currently most used by research institutions. We sustain the development of cell therapies that have the potential to fundamentally improve healthcare.
By harnessing the potential of a patient’s own plasma, bone marrow, or adipose tissue, patients can have more treatment options. We provide the systems for separating, concentrating, and processing autologous cells in clinical settings.